ISIS Pharmaceuticals, Inc. Stock Nasdaq
Equities
US4643301090
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 631M | Sales 2025 * | 768M | Capitalization | 5.96B |
---|---|---|---|---|---|
Net income 2024 * | -576M | Net income 2025 * | -514M | EV / Sales 2024 * | 9.27 x |
Net cash position 2024 * | 111M | Net Debt 2025 * | 223M | EV / Sales 2025 * | 8.05 x |
P/E ratio 2024 * |
-10.2
x | P/E ratio 2025 * |
-11.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.14% |
Latest transcript on ISIS Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
D. Walke
FOU | Founder | 58 | 12-06-30 |
Brett Monia
FOU | Founder | 62 | 89-01-09 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 62 | 00-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
CHM | Chairman | 72 | 14-02-02 |
Brett Monia
FOU | Founder | 62 | 89-01-09 |
Joan Herman
BRD | Director/Board Member | 70 | 19-06-09 |
1st Jan change | Capi. | |
---|---|---|
-1.78% | 41.36B | |
+45.55% | 41.3B | |
+4.01% | 39.61B | |
-15.14% | 25.62B | |
+3.16% | 24.09B | |
-24.08% | 18.38B | |
-2.67% | 11.82B | |
+24.76% | 11.85B | |
+7.01% | 11.07B |